EP4512424B1 - Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom - Google Patents

Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom

Info

Publication number
EP4512424B1
EP4512424B1 EP25150453.6A EP25150453A EP4512424B1 EP 4512424 B1 EP4512424 B1 EP 4512424B1 EP 25150453 A EP25150453 A EP 25150453A EP 4512424 B1 EP4512424 B1 EP 4512424B1
Authority
EP
European Patent Office
Prior art keywords
preservative
eye drops
tafluprost
free
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP25150453.6A
Other languages
English (en)
French (fr)
Other versions
EP4512424A2 (de
EP4512424A3 (de
Inventor
Timo Reunamaki
Pertti Pellinen
Olli Oksala
Kari Lehmussaari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
AGC Inc
Original Assignee
Asahi Glass Co Ltd
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39940592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP4512424(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Glass Co Ltd, Santen Pharmaceutical Co Ltd filed Critical Asahi Glass Co Ltd
Publication of EP4512424A2 publication Critical patent/EP4512424A2/de
Publication of EP4512424A3 publication Critical patent/EP4512424A3/de
Application granted granted Critical
Publication of EP4512424B1 publication Critical patent/EP4512424B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (7)

  1. Konservierungsmittelfreie Prostaglandin-Augentropfen zur einmaligen Anwendung bei Glaukompatienten, wobei die konservierungsmittelfreien Prostaglandin-Augentropfen in einem im Wesentlichen aus Polyethylen niedriger Dichte bestehenden Behälter mit 0,2-0,5 ml einer Lösung, die 0,0010-0,0025 % Tafluprost als ein Wirkstoff, 0,05-0,1 % Polysorbat 80 und 0,01-0,1 % Dinatriumedetat enthält, abgefüllt sind.
  2. Konservierungsmittelfreie Prostaglandin-Augentropfen nach Anspruch 1, wobei die Menge an Polysorbat 80 0,075 % beträgt.
  3. Konservierungsmittelfreie Prostaglandin-Augentropfen nach Anspruch 1, wobei die Menge an Tafluprost 0,0015 % beträgt.
  4. Konservierungsmittelfreie Prostaglandin-Augentropfen nach Anspruch 1, wobei die konservierungsmittelfreien Prostaglandin-Augentropfen mindestens einen weiteren pharmazeutisch wirksamen Stoff, wie beispielsweise Timolol, enthalten.
  5. Konservierungsmittelfreie Prostaglandin-Augentropfen nach Anspruch 1, wobei die konservierungsmittelfreien Prostaglandin-Augentropfen weiter Pufferstoffe enthalten.
  6. Konservierungsmittelfreie Prostaglandin-Augentropfen nach Anspruch 1, wobei die konservierungsmittelfreien Prostaglandin-Augentropfen weiter Tonizitätsmittel enthalten.
  7. Konservierungsmittelfreie Prostaglandin-Augentropfen nach Anspruch 1, wobei die konservierungsmittelfreien Prostaglandin-Augentropfen weiter 2,25 % Glycerin, 0,2 % Natriumdihydrogenphosphat-Dihydrat und pH-Regulatoren enthalten.
EP25150453.6A 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom Active EP4512424B1 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP08397513A EP2127638A1 (de) 2008-05-30 2008-05-30 Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
EP23202597.3A EP4289446B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom
EP17000440.2A EP3205334B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom
EP09754864.8A EP2306977B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom
PCT/JP2009/060211 WO2009145356A1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP20164602.3A EP3714877B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom
EP14001862.3A EP2772249B1 (de) 2008-05-30 2009-05-28 Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
EP21217057.5A EP4035656B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom

Related Parent Applications (7)

Application Number Title Priority Date Filing Date
EP21217057.5A Division EP4035656B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom
EP14001862.3A Division EP2772249B1 (de) 2008-05-30 2009-05-28 Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
EP09754864.8A Division EP2306977B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom
EP23202597.3A Division EP4289446B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom
EP23202597.3A Division-Into EP4289446B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom
EP20164602.3A Division EP3714877B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom
EP17000440.2A Division EP3205334B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom

Publications (3)

Publication Number Publication Date
EP4512424A2 EP4512424A2 (de) 2025-02-26
EP4512424A3 EP4512424A3 (de) 2025-03-05
EP4512424B1 true EP4512424B1 (de) 2026-03-18

Family

ID=39940592

Family Applications (8)

Application Number Title Priority Date Filing Date
EP08397513A Withdrawn EP2127638A1 (de) 2008-05-30 2008-05-30 Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
EP25150453.6A Active EP4512424B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom
EP21217057.5A Active EP4035656B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom
EP20164602.3A Revoked EP3714877B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom
EP14001862.3A Revoked EP2772249B1 (de) 2008-05-30 2009-05-28 Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
EP09754864.8A Active EP2306977B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom
EP17000440.2A Revoked EP3205334B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom
EP23202597.3A Active EP4289446B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP08397513A Withdrawn EP2127638A1 (de) 2008-05-30 2008-05-30 Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom

Family Applications After (6)

Application Number Title Priority Date Filing Date
EP21217057.5A Active EP4035656B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom
EP20164602.3A Revoked EP3714877B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom
EP14001862.3A Revoked EP2772249B1 (de) 2008-05-30 2009-05-28 Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
EP09754864.8A Active EP2306977B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom
EP17000440.2A Revoked EP3205334B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom
EP23202597.3A Active EP4289446B1 (de) 2008-05-30 2009-05-28 Verfahren und zusammensetzung zur behandlung von augenhochdruck und glaukom

Country Status (27)

Country Link
US (3) US9999593B2 (de)
EP (8) EP2127638A1 (de)
JP (9) JP2011521943A (de)
KR (5) KR101650006B1 (de)
CN (1) CN102083413B (de)
AR (2) AR071937A1 (de)
AU (1) AU2009252210C1 (de)
BR (1) BRPI0913109B8 (de)
CA (2) CA2724194C (de)
CY (2) CY1115565T1 (de)
DK (4) DK2772249T3 (de)
EA (1) EA023661B1 (de)
ES (6) ES2907982T3 (de)
GE (1) GEP20156220B (de)
HR (4) HRP20220361T1 (de)
HU (3) HUE049923T2 (de)
JO (1) JO3039B1 (de)
LT (3) LT2772249T (de)
MX (1) MX2010012987A (de)
MY (1) MY159463A (de)
PL (4) PL2306977T3 (de)
PT (4) PT3714877T (de)
SG (1) SG191628A1 (de)
SI (4) SI2772249T1 (de)
TW (1) TWI432202B (de)
UA (1) UA102257C2 (de)
WO (1) WO2009145356A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (de) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
EP2228058A1 (de) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
EP2389939A1 (de) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
JP5681472B2 (ja) * 2009-12-28 2015-03-11 ロート製薬株式会社 眼科用組成物
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US10154923B2 (en) * 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
RU2624534C2 (ru) 2010-07-29 2017-07-04 Аллерган, Инк. Растворы биматопроста и тимолола, не содержащие консервантов
US9061034B2 (en) * 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
AU2011282679A1 (en) * 2010-07-29 2013-03-07 Allergan, Inc. Preservative free bimatoprost solutions
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
EP2618810B1 (de) * 2010-09-21 2016-11-23 S & V Technologies GmbH Kosmetische zusammensetzung
EP2452669A1 (de) * 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmische Zusammensetzung
KR20140038404A (ko) * 2011-04-12 2014-03-28 가부시키가이샤 아루떼꾸 우에노 수성 안과용 조성물
CN102716074B (zh) * 2012-06-28 2013-10-16 武汉武药科技有限公司 一种贝美前列素滴眼剂及其制备方法
WO2014032026A1 (en) 2012-08-24 2014-02-27 Mitra Ashim K Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
EP3091985B1 (de) 2014-01-10 2024-05-08 Manistee Therapeutics, Inc. Prostanglandine für die topische anwendung bei der behandlung von migräne.
CN104766952B (zh) * 2015-04-21 2017-01-25 武汉凯迪工程技术研究总院有限公司 利用生物质气化炉滤渣制备锂离子电池负极材料的方法
ES2747302T3 (es) 2015-06-09 2020-03-10 Medproject Pharma Entw Und Vertriebsgesellschaft Mbh Gel oftálmico de bimatoprost aplicable en gotas
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
WO2017078953A1 (en) * 2015-11-06 2017-05-11 Accuitis Pharmaceuticals, Inc. Use of proteasome inhibitors to treat ocular disorders
PL3373976T3 (pl) 2015-11-10 2024-06-24 Sun Pharmaceutical Industries Limited Preparaty do stosowania miejscowego i ich zastosowanie
MX2018010395A (es) 2016-02-29 2018-11-29 Sun Pharma Global Fze Formulaciones topicas que contienen cliclosporina y usos de las mismas.
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
KR101770324B1 (ko) * 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
KR20190128657A (ko) * 2017-03-27 2019-11-18 코와 가부시키가이샤 의약 제제
US20180318319A1 (en) * 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
US11382887B2 (en) 2017-06-22 2022-07-12 Ys Life Science Co. Ltd. Ophthalmic composition for glaucoma treatment
EP4338751B1 (de) * 2017-12-21 2025-09-03 Santen Pharmaceutical Co., Ltd. Kombination von sepetaprost und netarsudil zur verwendung in der prophylaxe oder behandlung von glaukom oder augenhochdruck
WO2020013717A1 (en) 2018-07-09 2020-01-16 Warszawskie Zaklady Farmaceutyczne Polfa Sa Ophthalmic dispensing device
JP7599838B2 (ja) * 2019-04-10 2024-12-16 参天製薬株式会社 エピナスチン又はその塩を含有する水性医薬組成物
CN111632025A (zh) * 2020-03-04 2020-09-08 吉林大学第一医院 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法
RU2761625C2 (ru) * 2021-02-11 2021-12-13 Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") Фармацевтическая композиция тафлупроста
CN116687842A (zh) * 2022-02-28 2023-09-05 山东新时代药业有限公司 一种拉坦前列素滴眼液及其制备方法
US20250213510A1 (en) * 2022-03-25 2025-07-03 Tsubota Laboratory, Inc. Aqueous Composition
CN119384280A (zh) * 2022-06-16 2025-01-28 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用
TW202444342A (zh) * 2023-03-24 2024-11-16 日商坪田實驗室股份有限公司 水性組成物
WO2024232425A1 (ja) * 2023-05-11 2024-11-14 テイカ製薬株式会社 プロスタグランジンＦ２α誘導体の含有率低下が抑制されている製品
JP7757564B1 (ja) 2024-06-28 2025-10-21 東亜薬品株式会社 水性組成物
GR1011143B (el) * 2025-04-11 2026-03-02 Ιουλια Τσετη Οφθαλμικο διαλυμα προσταγλανδινης χωρις συντηρητικα

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
EP0286903B2 (de) 1987-04-03 2000-03-29 The Trustees Of Columbia University In The City Of New York Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
DE4027320C2 (de) 1990-08-29 1993-09-30 Ursapharm Arzneimittel Gmbh Fluid-Abgabeeinrichtung für keimfreies Fluid
JPH0655640A (ja) 1992-08-04 1994-03-01 Aavan Internatl:Kk 洗面台カウンター及びその製造方法
JPH06107547A (ja) 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
JP2510066Y2 (ja) 1993-01-20 1996-09-11 東洋製罐株式会社 加熱殺菌可能な液体医薬容器
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
CA2237898A1 (en) * 1995-11-17 1997-05-29 Louis Desantis Jr. Combination therapy for treating glaucoma
EP0930296B2 (de) 1996-09-17 2005-11-02 Asahi Glass Company Ltd. Fluorierte prostaglandinderivate und medikamente
CA2273837C (en) 1996-12-09 2003-12-30 Bausch & Lomb Incorporated Single-use flexible container
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
DE69834638T2 (de) * 1997-10-13 2007-05-10 R-Tech Ueno, Ltd. Zusammensetzung zur Behandlung von Augenhypertension oder Glaukom
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
GB2337740B (en) 1998-05-26 2000-11-15 Spreckelsen Mcgeough Ltd Fluid packaging
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
DE69922916T2 (de) * 1998-07-14 2005-06-09 Alcon Manufacturing Ltd., Fort Worth Polypropylenbasierte behälter für prostaglandin-enthaltende produkte
WO2000018316A2 (en) 1998-09-25 2000-04-06 Alcon Laboratories, Inc. Sustained release, and comfortable ophthalmic composition and method for ocular therapy
US6096783A (en) 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
HUP0200898A3 (en) 1999-04-06 2005-09-28 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
AU2001264261A1 (en) 2000-06-19 2002-01-02 Santen Pharmaceutical Co. Ltd. Aseptics
CA2422031C (en) 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
JP3876355B2 (ja) * 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
TW586946B (en) 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
JP4402591B2 (ja) 2002-07-16 2010-01-20 千寿製薬株式会社 薬液容器及びその製造方法
CA2707067C (en) * 2002-09-09 2013-07-16 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
ATE450264T1 (de) * 2003-07-31 2009-12-15 Santen Pharmaceutical Co Ltd Prostaglandin enthaltendes produkt
US20050287325A1 (en) * 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
EP1655021B1 (de) * 2004-11-09 2008-10-29 Novagali Pharma SA Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
US7562796B2 (en) 2004-11-24 2009-07-21 Holopack International Corp. Dispensing container with flow control system
ES2588581T3 (es) 2004-12-09 2016-11-03 Santen Pharmaceutical Co., Ltd. Producto que contiene prostaglandina con átomo de flúor en su molécula
DK1829545T3 (da) 2004-12-24 2012-07-23 Santen Pharmaceutical Co Ltd Produkter indeholdende prostaglandin-F2alfa-derivat
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
CN101222939B (zh) 2005-07-13 2010-11-24 参天制药株式会社 眼科用防腐组合物
US8030349B2 (en) * 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
PT1937212E (pt) 2005-10-10 2010-11-30 Novagali Pharma Sa Emulsões oftálmicas contendo prostaglandinas
FI126233B (sv) 2006-02-23 2016-08-31 Oy Kwh Mirka Ab Oscillerande slipmaskin
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
KR100927617B1 (ko) 2007-11-26 2009-11-23 한국표준과학연구원 열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법
EP2127638A1 (de) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom

Also Published As

Publication number Publication date
JP2016065095A (ja) 2016-04-28
LT2772249T (lt) 2017-09-11
JP6649992B2 (ja) 2020-02-19
HRP20220361T1 (hr) 2022-05-13
HRP20200998T1 (hr) 2020-10-16
BRPI0913109A2 (pt) 2017-06-20
MX2010012987A (es) 2011-02-24
EP4512424A2 (de) 2025-02-26
JP2021120412A (ja) 2021-08-19
GEP20156220B (en) 2015-01-26
MY159463A (en) 2017-01-13
KR102114401B1 (ko) 2020-05-25
US20180289618A1 (en) 2018-10-11
JP2020073574A (ja) 2020-05-14
ES2627837T3 (es) 2017-07-31
PL2306977T3 (pl) 2015-01-30
US10864159B2 (en) 2020-12-15
SI3714877T1 (sl) 2022-05-31
DK2772249T3 (en) 2017-07-17
EA201071413A1 (ru) 2011-06-30
JP2018154656A (ja) 2018-10-04
KR20190067272A (ko) 2019-06-14
EP4289446B1 (de) 2025-02-12
EP3205334A1 (de) 2017-08-16
EP4035656B1 (de) 2023-11-22
JP2017178957A (ja) 2017-10-05
PL3714877T3 (pl) 2022-05-16
JP6356868B2 (ja) 2018-07-11
JP6148317B2 (ja) 2017-06-14
LT3714877T (lt) 2022-04-11
HUE058079T2 (hu) 2022-06-28
JP2024079852A (ja) 2024-06-11
PL2772249T3 (pl) 2017-10-31
DK3205334T3 (da) 2020-07-13
EP2772249B1 (de) 2017-05-03
CA2724194A1 (en) 2009-12-03
EP4512424A3 (de) 2025-03-05
ES2808050T3 (es) 2021-02-25
EP4289446A2 (de) 2023-12-13
EP2127638A1 (de) 2009-12-02
KR101988642B1 (ko) 2019-06-12
ES3014089T3 (en) 2025-04-16
PT3205334T (pt) 2020-07-31
SI2772249T1 (sl) 2017-08-31
KR20110011707A (ko) 2011-02-08
DK3714877T3 (da) 2022-02-14
EP3714877B1 (de) 2022-01-26
HRP20140979T1 (hr) 2014-11-21
US9999593B2 (en) 2018-06-19
US20110152264A1 (en) 2011-06-23
DK2306977T3 (da) 2014-09-15
AR120961A2 (es) 2022-04-06
SI2306977T1 (sl) 2014-12-31
SI3205334T1 (sl) 2020-10-30
WO2009145356A1 (en) 2009-12-03
KR101650006B1 (ko) 2016-08-22
EP2772249A1 (de) 2014-09-03
EP2306977B1 (de) 2014-08-13
CN102083413B (zh) 2013-11-06
EP2306977A1 (de) 2011-04-13
EP3714877A1 (de) 2020-09-30
AU2009252210B2 (en) 2014-10-16
JP2014133765A (ja) 2014-07-24
AR071937A1 (es) 2010-07-28
JP7520285B2 (ja) 2024-07-23
EP4289446A3 (de) 2024-01-10
SG191628A1 (en) 2013-07-31
UA102257C2 (uk) 2013-06-25
JP7265584B2 (ja) 2023-04-26
ES2968837T3 (es) 2024-05-14
ES2495316T3 (es) 2014-09-17
KR101820816B1 (ko) 2018-01-22
JP2011521943A (ja) 2011-07-28
KR20160102319A (ko) 2016-08-29
PT3714877T (pt) 2022-03-10
HRP20170769T1 (hr) 2017-08-11
LT3205334T (lt) 2020-09-25
TW201000104A (en) 2010-01-01
AU2009252210A1 (en) 2009-12-03
KR20180008905A (ko) 2018-01-24
TWI432202B (zh) 2014-04-01
KR102246598B1 (ko) 2021-04-30
CY1115565T1 (el) 2017-01-04
CY1120351T1 (el) 2019-07-10
PT2772249T (pt) 2017-08-08
CN102083413A (zh) 2011-06-01
US20210059931A1 (en) 2021-03-04
BRPI0913109B1 (pt) 2019-10-22
CA2965185A1 (en) 2009-12-03
PL3205334T3 (pl) 2020-11-02
ES2907982T3 (es) 2022-04-27
KR20200057801A (ko) 2020-05-26
JP2023085558A (ja) 2023-06-20
AU2009252210C1 (en) 2016-04-14
HUE033103T2 (en) 2017-11-28
JP6889789B2 (ja) 2021-06-18
EA023661B1 (ru) 2016-06-30
BRPI0913109B8 (pt) 2021-05-25
EP4035656A1 (de) 2022-08-03
HUE049923T2 (hu) 2020-11-30
ES2627837T8 (es) 2018-02-26
PT2306977E (pt) 2014-09-22
JO3039B1 (ar) 2016-09-05
EP3205334B1 (de) 2020-04-29
CA2724194C (en) 2017-06-27

Similar Documents

Publication Publication Date Title
US10864159B2 (en) Method and composition for treating ocular hypertension and glaucoma

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0047180000

Ipc: A61K0009080000

Ref country code: DE

Ref legal event code: R079

Ref document number: 602009065663

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0047180000

Ipc: A61K0009080000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AC Divisional application: reference to earlier application

Ref document number: 2306977

Country of ref document: EP

Kind code of ref document: P

Ref document number: 2772249

Country of ref document: EP

Kind code of ref document: P

Ref document number: 3205334

Country of ref document: EP

Kind code of ref document: P

Ref document number: 3714877

Country of ref document: EP

Kind code of ref document: P

Ref document number: 4035656

Country of ref document: EP

Kind code of ref document: P

Ref document number: 4289446

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/18 20170101ALI20250129BHEP

Ipc: A61K 47/26 20060101ALI20250129BHEP

Ipc: A61K 47/10 20170101ALI20250129BHEP

Ipc: A61K 31/5575 20060101ALI20250129BHEP

Ipc: A61K 9/08 20060101AFI20250129BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

17P Request for examination filed

Effective date: 20250904

INTG Intention to grant announced

Effective date: 20251007

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: UPC_APP_0000643_4512424/2026

Effective date: 20260108

AC Divisional application: reference to earlier application

Ref document number: 4289446

Country of ref document: EP

Kind code of ref document: P

Ref document number: 4035656

Country of ref document: EP

Kind code of ref document: P

Ref document number: 3714877

Country of ref document: EP

Kind code of ref document: P

Ref document number: 3205334

Country of ref document: EP

Kind code of ref document: P

Ref document number: 2772249

Country of ref document: EP

Kind code of ref document: P

Ref document number: 2306977

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: F10

Free format text: ST27 STATUS EVENT CODE: U-0-0-F10-F00 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260318

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009065663

Country of ref document: DE